Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[ 211At]astato-3-pyridinecarboxylate
Monoclonal antibodies (MAbs) such as the anti-epidermal growth factor variant III (EGFRvIII) MAb L8A4 are rapidly internalized, which can lead to rapid loss of radioactivity from the tumor cell. The aim of this study was to evaluate the potential utility of N-succinimidyl 5-[ 211At]astato-3-pyridine...
Saved in:
Published in | Nuclear medicine and biology Vol. 26; no. 4; pp. 405 - 411 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Amsterdam
Elsevier Inc
01.05.1999
Elsevier |
Subjects | |
Online Access | Get full text |
ISSN | 0969-8051 1872-9614 |
DOI | 10.1016/S0969-8051(98)00120-6 |
Cover
Summary: | Monoclonal antibodies (MAbs) such as the anti-epidermal growth factor variant III (EGFRvIII) MAb L8A4 are rapidly internalized, which can lead to rapid loss of radioactivity from the tumor cell. The aim of this study was to evaluate the potential utility of
N-succinimidyl 5-[
211At]astato-3-pyridinecarboxylate ([
211At]SAPC) for labeling murine L8A4 with
211At. SAPC was synthesized by astatodestannylation of
N-succinimidyl 5-tri-
n-butylstannyl 3-pyridinecarboxylate and then coupled to L8A4 in approximately 50% yield. The affinity and immunoreactive fraction for
211At-labeled L8A4 were comparable to those obtained when the MAb was labeled with
131I via
N-succinimidyl 5-[
131I]iodo-3-pyridinecarboxylate (SIPC). Paired-label comparisons of the
211At- and
131I-labeled MAbs demonstrated similar internalization and catabolism by EGFRvIII-positive cells
in vitro, and with the exception of the stomach, similar tissue distribution in athymic mice with EGFRvIII-expressing U87MGΔEGFR xenografts. These results suggest that SAPC may be a useful reagent for labeling L8A4, and possibly other internalizing proteins, with
211At. |
---|---|
ISSN: | 0969-8051 1872-9614 |
DOI: | 10.1016/S0969-8051(98)00120-6 |